The Analyst Landscape: 4 Takes On Absci
Portfolio Pulse from Benzinga Insights
In the past three months, Absci (NASDAQ:ABSI) received varied analyst ratings, with a notable shift towards bullish perspectives in the last 30 days. The average 12-month price target for ABSI has significantly increased to $7.25 from $4.00, indicating a positive outlook from analysts. Absci, an AI-powered synthetic biology company, faces challenges with a -68.59% revenue decline and a net margin of -2956.18%, yet it maintains a strong financial performance with exceptional ROE and ROA figures.
March 06, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Absci has seen a positive shift in analyst ratings with an increased average price target of $7.25, reflecting optimism despite a significant revenue decline and a high net margin loss.
The increase in Absci's average price target to $7.25 from $4.00, along with the shift towards more bullish ratings, suggests a positive outlook from analysts. Despite the revenue decline and negative net margin, the company's strong ROE and ROA indicate a solid financial foundation, which could drive investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100